Oncolytics ESMO abstract details 60-patient REO 033 colorectal study; prior REO 022 showed 17-month PFS vs 6

ONCOLYTICS BIOTECH INC

REO 033 randomized, open-label Phase 2 study enrolls 30 patients per arm: pelareorep + FOLFIRI + bevacizumab vs FOLFIRI + bevacizumab in 2L RAS-mutant MSS mCRC.
Primary endpoint is objective response rate; secondary endpoints include OS, PFS, disease control rate, duration of response, safety/tolerability, and biomarker sampling.
Recent FDA interactions enable pivotal Part B expansion of REO 033, potentially supporting accelerated approval based on ORR and full approval based on PFS.
Prior REO 022 in 2L KRAS-mutant MSS mCRC more than doubled ORR, median PFS, OS and DOR versus historical FOLFIRI/bevacizumab; headline cites 17-month PFS vs 6 months.
Abstract 994eTiP e-poster at ESMO Congress 2026; lead investigator Sanjay Goel cited conviction pelareorep can meaningfully impact patients.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.